Prognosis and duration of disabling effects

In the rare situation where care and mobility needs are identified because of treatment of stage 1, 2 or 3 endometrial cancer, any award made should last for the duration of treatment as typically improvement is expected. In stage 4 and recurrent disease needs are likely to increase over time.

Stage 1 and 2 disease

Five year survival from stage 1 disease is about 95%.

Five year survival from stage 2 disease is 80-90%.

Stage 3 disease

Five year survival from stage 3 disease is 50-60%.

Stage 4 disease

Five year survival for stage 4 disease is about 26%.

Most of these people are terminally ill.

Metastatic and Recurrent disease

This person is likely to be terminally ill although the expected survival may be longer than six months.

The majority of women have early stage disease but some of these women will experience recurrence of their endometrial cancer. After treatment endometrial cancer may recur either as a growth in the pelvis or more usually somewhere else in the body.

For those with locally advanced disease like stage 4 disease, recurrence is very likely even when primary treatment is successful. The aim of treatment in stage 4 disease is to control the disease for as long as possible.

Amended April 2008